Price
$26.49
Increased by +1.07%
Dollar volume (20D)
73.52 M
ADR%
5.61
Earnings report date
Feb 20, 2025
Shares float
128.17 M
Shares short
17.00 M [13.26%]
Shares outstanding
188.99 M
Market cap
4.95 B
Beta
1.09
Price/earnings
N/A
20D range
22.47 30.51
50D range
21.72 30.51
200D range
21.62 32.06

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases.

BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 1, 24 -0.86
Increased by +20.41%
-0.98
Increased by +12.29%
Aug 1, 24 -0.39
Increased by +60.20%
-1.06
Increased by +63.21%
May 2, 24 -0.20
Increased by +78.26%
-0.71
Increased by +71.83%
Feb 22, 24 -0.96
Decreased by -4.35%
-0.91
Decreased by -5.49%
Nov 2, 23 -1.08
Decreased by -16.13%
-0.82
Decreased by -31.71%
Aug 3, 23 -0.98
Decreased by -1.30 K%
-0.83
Decreased by -18.07%
May 4, 23 -0.92
Increased by +22.69%
-0.83
Decreased by -10.84%
Feb 23, 23 -0.92
Increased by +8.91%
-0.85
Decreased by -8.24%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 2.73 M
Decreased by -33.22%
-162.04 M
Increased by +8.45%
Decreased by -5.93 K%
Decreased by -37.09%
Jun 30, 24 2.17 M
Increased by +32.11%
-73.46 M
Increased by +53.48%
Decreased by -3.39 K%
Increased by +64.79%
Mar 31, 24 211.12 M
Increased by +11.46 K%
-35.22 M
Increased by +80.09%
Decreased by -16.68%
Increased by +99.83%
Dec 31, 23 1.75 M
Decreased by -6.68%
-168.15 M
Decreased by -7.81%
Decreased by -9.64 K%
Decreased by -15.53%
Sep 30, 23 4.09 M
Increased by +1.11 K%
-177.00 M
Decreased by -19.26%
Decreased by -4.33 K%
Increased by +90.15%
Jun 30, 23 1.64 M
Decreased by -97.77%
-157.90 M
Decreased by -365.98%
Decreased by -9.62 K%
Decreased by -12.05 K%
Mar 31, 23 1.83 M
Increased by +7.79%
-176.85 M
Increased by +28.32%
Decreased by -9.68 K%
Increased by +33.50%
Dec 31, 22 1.87 M
Decreased by -85.49%
-155.97 M
Decreased by -5.98%
Decreased by -8.34 K%
Decreased by -630.27%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY